{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/08/26/3351235/0/en/bridgebio-announces-first-participant-dosed-in-ascend-attr-a-phase-3b-4-study-evaluating-the-long-term-effects-of-acoramidis-on-disease-regression-in-attr-cm.html", "message": "News view counter 902769 successfully enlarged"}